ImmunityBio (IBRX) Payables (2016 - 2025)
Historic Payables for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $43.6 million.
- ImmunityBio's Payables rose 862040.0% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 862040.0%. This contributed to the annual value of $40.6 million for FY2024, which is 498.27% down from last year.
- Per ImmunityBio's latest filing, its Payables stood at $43.6 million for Q3 2025, which was up 862040.0% from $35.7 million recorded in Q2 2025.
- ImmunityBio's 5-year Payables high stood at $544.2 million for Q2 2023, and its period low was $44000.0 during Q2 2024.
- Its 5-year average for Payables is $159.2 million, with a median of $42.7 million in 2023.
- As far as peak fluctuations go, ImmunityBio's Payables plummeted by 9999.19% in 2024, and later surged by 8104772.73% in 2025.
- Over the past 5 years, ImmunityBio's Payables (Quarter) stood at $350.6 million in 2021, then soared by 35.11% to $473.7 million in 2022, then plummeted by 90.98% to $42.7 million in 2023, then dropped by 4.98% to $40.6 million in 2024, then increased by 7.45% to $43.6 million in 2025.
- Its Payables stands at $43.6 million for Q3 2025, versus $35.7 million for Q2 2025 and $27.9 million for Q1 2025.